Interfering with the paracrine function of VEGF alters local glomerular physiology, resulting in clinical and pathological manifestations of kidney damage, such as proteinuria, nephrotic syndrome, acute kidney injury, thrombotic microangiopathy (TMA), and hypertension observed with the administration of VEGF ligand inhibitors [61]. This evidence concerns the gene VEGFA and thrombotic microangiopathy.